Company Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel.

It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations.

The company was incorporated in 2007 and is based in Tel Aviv, Israel.

PainReform Ltd.

Country	Israel
Founded	2007
IPO Date	Sep 1, 2020
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	7
CEO	Ilan Hadar M.B.A.

Contact Details

Address: 65 Yigal Alon St. Tel Aviv, L3 6744316 Israel
Phone	972-3-7177051
Website	painreform.com

Stock Details

Ticker Symbol	PRFX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$8.00
CIK Code	0001801834
CUSIP Number	M77798102
ISIN Number	IL0011651580
SIC Code	2834

Key Executives

Name	Position
Dr. Ehud Geller Ph.D.	Executive Chairman
Ilan Hadar M.B.A.	Chief Executive Officer and Chief Financial Officer
Dr. Sigal Aviel	Chief Operating Officer
Prof. Eli Hazum Ph.D.	Chief Technology Officer and Director
Rita Keynan	Vice President of Pharmaceutical Operations
Dr. Stephen A. Cooper D.M.D Ph.D.	Executive Vice President of Development

Latest SEC Filings

Date	Type	Title
Apr 24, 2024	SC 13G	Statement of acquisition of beneficial ownership by individuals
Apr 17, 2024	6-K	Report of foreign issuer
Apr 17, 2024	424B3	Prospectus
Apr 17, 2024	424B4	Prospectus
Apr 16, 2024	6-K	Report of foreign issuer
Apr 15, 2024	EFFECT	Notice of Effectiveness
Apr 15, 2024	F-1/A	[Amend] Registration statement for certain foreign private issuers
Apr 9, 2024	6-K	Report of foreign issuer
Apr 8, 2024	6-K	Report of foreign issuer
Apr 2, 2024	6-K	Report of foreign issuer

View All SEC Filings